The thoracic oncology community is discussing targeted therapies for various driver mutations, including the next-generation KRAS G12C inhibitor divarasib, which showed improved survival in the Krascendo 1 trial. There is also significant conversation around perioperative immunotherapy in resectable NSCLC, with trials like KEYNOTE-671 and CheckMate 816 cited for establishing improved outcomes. Other topics include ADCs like Trastuzumab Deruxtecan for HER2-altered disease and the potential of APOBEC mutational signatures as a predictive biomarker for ICI benefit.
“Next gen Kras G12C, divarasib, improves survival in 2nd line lung cancer in Krascendo 1.”
— @FordePatrick · KRAS G12C inhibitor · View post ↗📌 Amplified by @KolPulseAI
“Perioperative immunotherapy has reshaped resectable NSCLC.”
— @K_Yadavir · Perioperative Immunotherapy · View post ↗📌 Amplified by @KolPulseAI
“🔥APOBEC mutational signatures predict ICI benefit in TMB-low metastatic NSCLC independent of PD-L1”
— @HHorinouchi · Biomarkers for ICI · View post ↗📌 Amplified by @KolPulseAI
The breast oncology community is discussing the role of circulating tumor DNA (ctDNA) in guiding treatment for early-stage disease. There is also focus on new trial data, including the HORIZON-Breast01 interim analysis of trastuzumab rezetecan in HER2-positive metastatic breast cancer. Other topics include treatment algorithms for early HR+/HER2- disease and the implications of GLP-1 receptor agonists for patients.
“Trastuzumab rezetecan (SHR-A1811), a HER2-directed antibody-drug conjugate with a topoisomerase I inhibitor payload, beat pyrotinib plus capecitabine in HER2-positive metastatic breast”
— @Markuseckstein3 · HORIZON-Breast01 trial · View post ↗📌 Amplified by @KolPulseAI
“Multiple ongoing prospective interventional trials are evaluating whether ctDNA-guided treatment escalation or de-escalation can improve patient outcomes and support the routine implementation of ctDNA”
— @VivekSubbiah · ctDNA in early breast cancer · View post ↗
“Only half of metastatic TNBC patients make it to a second line of treatment. This stark reality underscores why the first frontline decision is everything.”
— @CHMediaHub · Metastatic TNBC treatment · View post ↗The GI oncology community is discussing trial data, primarily from ESMO-GI. In pancreatic cancer (PDAC), zoldonrasib showed promising response rates in RAS G12D-mutated disease, while the GLEAM study of zolbetuximab did not meet its primary endpoint. In hepatocellular carcinoma (HCC), EMERALD-3 showed improved PFS and ORR with STRIDE plus TACE, while EMERALD-1 did not show an overall survival benefit.
“Safety and efficacy of zoldonrasib plus chemotherapy in 1L RAS G12D metastatic PDAC @ ESMO-GI 👏amazing response rates”
— @ArndtVogel · Zoldonrasib in PDAC · View post ↗📌 Amplified by @KolPulseAI
“Zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2+ metastatic PDAC: phase II GLEAM study @ESMO-GI 👉Primary endpoint not met, no OS & PFS benefit”
— @ArndtVogel · Zolbetuximab (GLEAM) in PDAC · View post ↗📌 Amplified by @KolPulseAI
“Adding STRIDE + TACE significantly improved PFS, ORR and DoR versus TACE alone, with a manageable safety profile.”
— @SuyogCancer · EMERALD-3 in HCC · View post ↗📌 Amplified by @KolPulseAI
The GU oncology community is discussing new data in clear cell renal cell carcinoma (ccRCC). The LITESPARK-022 trial showed adjuvant belzutifan plus pembrolizumab improved disease-free survival in high-risk ccRCC post-nephrectomy, though with increased toxicity and immature overall survival. Additionally, results from the ARC20 trial of the HIF-2α inhibitor Casdatifan in heavily pretreated advanced ccRCC are being noted.
“24-month DFS: 80.7% vs 73.7% (HR 0.72; P<0.001). OS not yet significant at interim.”
— @drenriquegrande · LITESPARK-022 trial data · View post ↗
“Adjuvant kidney cancer: adding belzutifan to pembro cuts recurrences, but there was increase in grade 3 toxicity and overall survival is still immature.”
— @katy_beckermann · LITESPARK-022 commentary · View post ↗📌 Amplified by @KolPulseAI
“This trial evaluated the HIF-2α inhibitor Casdatifan in heavily pretreated advanced ccRCC and provides important insights into HIF-2α biology and response.”
— @DrChoueiri · ARC20 trial · View post ↗📌 Amplified by @KolPulseAI
The myeloma/hematology community is discussing advanced therapies, including the sequencing of CAR-T versus bispecifics after initial BCMA therapy failure and the mechanisms of relapse post-CAR T. A new analysis of global clinical trials over the past 20 years is also a key topic, highlighting expanded research in immunotherapy and targeted therapies but unequal access to innovation.
“CAR-T vs Bispecifics — Which Performs Better in #Myeloma After Initial BCMA Therapy Fails?”
— @MyelomaTeacher · Sequencing therapies · View post ↗📌 Amplified by @KolPulseAI
“🧬 Why do most myeloma patients eventually relapse after CAR T therapy?”
— @YLeyfman · CAR-T relapse · View post ↗📌 Amplified by @KolPulseAI
“Our new USMIRC analysis evaluated 845 multiple myeloma clinical trials registered on https://t.co/M3vaaOWVX8 over the past 20 years, examining where trials are conducted, how they have evolved, and who has access to innovation.”
— @Abdallah81MD · Clinical trial landscape analysis · View post ↗The hematology community is discussing the publication of the PRISM Risk Model for prognosticating risk in AML patients treated with hypomethylating agents and venetoclax. There is also conversation around a newly approved stem cell transplant therapy (Tregzi) from the Precision-T trial, which demonstrated a reduction in chronic GVHD. Other topics include positive Phase 3 results for BRUKINSA in frontline mantle cell lymphoma and the TRANSFORM-1 trial in myelofibrosis.
“PRISM incorporates 17 clinical & genomic variables into a prognostic risk model that is better than ELN-2024.”
— @LeukDocJZ · PRISM Risk Model · View post ↗
“The Precision-T trial demonstrated a significant reduction in chronic GVHD using a precision-engineered graft enriched with donor regulatory T cells.”
— @HenrychihangFu1 · Tregzi / Precision-T Trial · View post ↗📌 Amplified by @KolPulseAI
“The treatment for AML is changing but our risk prognostication hadn’t- until now!”
— @TaylorJ_MD · PRISM Risk Model · View post ↗